Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients.

Rothschild, S I; Nachbur, R; Herzog, N; Passweg, J R; Pless, M

Rothschild, S I; Nachbur, R; Herzog, N; Passweg, J R; Pless, M.

Afiliación

Rothschild SI; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland; Lung Cancer Center Basel, Comprehensive Cancer Center, University Hospital Basel, Basel, Switzerland.
Nachbur R; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Herzog N; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Passweg JR; Division of Hematology, University Hospital Basel, Basel, Switzerland.
Pless M; Division of Medical Oncology and Hematology, Cantonal Hospital Winterthur, Winterthur, Switzerland. Electronic address: miklos.pless@ksw.ch.

ESMO Open ; 6(1): 100013, 2021 02.

Article en En | MEDLINE | ID: mdl-33422767

Asunto(s)

Carcinoma de Pulmón de Células no Pequeñas; Neoplasias Pulmonares; Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico; Humanos; Neoplasias Pulmonares/tratamiento farmacológico; Pronóstico

Palabras clave

chemotherapy; non-small cell lung cancer; refractory patients; second-line therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: ESMO Open Año: 2021 Tipo del documento: Article País de afiliación: Suiza

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google